Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia

Cell

Volumn 167, Issue 1, 2016, Pages 171-186.e15

  Sykes, David B ^a,b,g,h   Kfoury, Youmna S ^a,g,h   Mercier, François E ^a,g,h   Wawer, Mathias J ^c   Law, Jason M ^c,i   Haynes, Mark K ^d   Lewis, Timothy A ^c   Schajnovitz, Amir ^a,g,h   Jain, Esha ^a   Lee, Dongjun ^a,g,h   Meyer, Hanna ^e   Pierce, Kerry A ^c   Tolliday, Nicola J ^c   Waller, Anna ^d   Ferrara, Steven J ^c   Eheim, Ashley L ^e   Stoeckigt, Detlef ^e   Maxcy, Katrina L ^a   Cobert, Julien M ^a   Bachand, Jacqueline ^a   Szekely, Brian A ^a   Mukherjee, Siddhartha ^f   Sklar, Larry A ^d   Kotz, Joanne D ^c   Clish, Clary B ^c   Sadreyev, Ruslan I ^b   Clemons, Paul A ^c   Janzer, Andreas ^e   Schreiber, Stuart L ^c,i,j   Scadden, David T ^a,b,g,h   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e BAYER PHARMA AG   (Germany)

^f Columbia University School of Medicine ^*  (United States)

^g Harvard University   (United States)

^h HARVARD STEM CELL INSTITUTE   (United States)

ⁱ HARVARD UNIVERSITY   (United States)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

acute myeloid leukemia; brequinar; differentiation; dihydroorotate dehydrogenase; high throughput screen; HoxA9; leukemia initiating cell; metabolic inhibitor; phenotypic screen

Indexed keywords

ANTILEUKEMIC AGENT; BREQUINAR; DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; TRANSCRIPTION FACTOR HOXA9; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HOMEODOMAIN PROTEIN; MOLECULAR LIBRARY; OXIDOREDUCTASE; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CHEMISTRY; DRUG SCREENING; GENETICS; ISOLATION AND PURIFICATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MOLECULAR TARGETED THERAPY; MYELOID CELLS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRIMIDINES; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988602600     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.08.057     Document Type: Article

References (51)

1. Adamaki, M., Lambrou, G.I., Athanasiadou, A., Vlahopoulos, S., Papavassiliou, A.G., Moschovi, M., HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: significant correlation with relapse and overall survival. Leuk. Res. 39 (2015), 874–882.
2. Arteaga, C.L., Brown, T.D., Kuhn, J.G., Shen, H.S., O'Rourke, T.J., Beougher, K., Brentzel, H.J., Von Hoff, D.D., Weiss, G.R., Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Cancer Res. 49 (1989), 4648–4653.
3. Bond, M.R., Hanover, J.A., A little sugar goes a long way: the cell biology of O-GlcNAc. J. Cell Biol. 208 (2015), 869–880.
4. Bourgon, R., Gentleman, R., Huber, W., Independent filtering increases detection power for high-throughput experiments. Proc. Natl. Acad. Sci. USA 107 (2010), 9546–9551.
5. Burris, H.A. 3rd, Raymond, E., Awada, A., Kuhn, J.G., O'Rourke, T.J., Brentzel, J., Lynch, W., King, S.Y., Brown, T.D., Von Hoff, D.D., Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies. Invest. New Drugs 16 (1998), 19–27.
6. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368 (2013), 2059–2074.
7. Chattopadhyay, S., Stewart, A.L., Mukherjee, S., Huang, C., Hartwell, K.A., Miller, P.G., Subramanian, R., Carmody, L.C., Yusuf, R.Z., Sykes, D.B., et al. Niche-based screening in multiple myeloma identifies a kinesin-5 inhibitor with improved selectivity over hematopoietic progenitors. Cell Rep. 10 (2015), 755–770.
8. Collins, C.T., Hess, J.L., Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene 35 (2016), 1090–1098.
9. Cramer, D.V., Brequinar sodium. Pediatr. Nephrol. 9:Suppl (1995), S52–S55.
10. Dix, D.E., Lehman, C.P., Jakubowski, A., Moyer, J.D., Handschumacher, R.E., Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. Cancer Res. 39 (1979), 4485–4490.
11. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
12. Doscas, M.E., Williamson, A.J., Usha, L., Bogachkov, Y., Rao, G.S., Xiao, F., Wang, Y., Ruby, C., Kaufman, H., Zhou, J., et al. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia 16 (2014), 824–834.
13. Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., Huber, W., BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21 (2005), 3439–3440.
14. Faust, N., Varas, F., Kelly, L.M., Heck, S., Graf, T., Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 96 (2000), 719–726.
15. Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999), 531–537.
16. Hanover, J.A., Krause, M.W., Love, D.C., Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat. Rev. Mol. Cell Biol. 13 (2012), 312–321.
17. Haynes, M.K., Strouse, J.J., Waller, A., Leitao, A., Curpan, R.F., Bologa, C., Oprea, T.I., Prossnitz, E.R., Edwards, B.S., Sklar, L.A., Thompson, T.A., Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. J. Biomol. Screen. 14 (2009), 596–609.
18. Hesson, D.P. (1987). 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof. U.S. patent US4680299 A. http://www.google.com/patents/US4680299.
19. Huang, M., Wang, Y., Collins, M., Mitchell, B.S., Graves, L.M., A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Mol. Pharmacol. 62 (2002), 463–472.
20. Johnson, W.E., Li, C., Rabinovic, A., Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
21. Jóźwiak, P., Forma, E., Bryś, M., Krześlak, A., O-GlcNAcylation and metabolic reprograming in cancer. Front. Endocrinol. (Lausanne), 5, 2014, 145.
22. Knecht, W., Löffler, M., Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem. Pharmacol. 56 (1998), 1259–1264.
23. Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber, J., Levine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006), 818–822.
24. Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., Sauvageau, G., Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17 (1998), 3714–3725.
25. Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. Gruppo Italiano Malattie Ematologiche dell'Adulto German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369 (2013), 111–121.
26. Löffler, M., Jöckel, J., Schuster, G., Becker, C., Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. Cell. Biochem. 174 (1997), 125–129.
27. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
28. Mayers, J.R., Wu, C., Clish, C.B., Kraft, P., Torrence, M.E., Fiske, B.P., Yuan, C., Bao, Y., Townsend, M.K., Tworoger, S.S., et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20 (2014), 1193–1198.
29. Miller, R.W., Kerr, C.T., Curry, J.R., Mammalian dehydroorotate-ubiquinone reductase complex. Can. J. Biochem. 46 (1968), 1099–1106.
30. Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D., Shannon, P.T., Jabs, E.W., Nickerson, D.A., et al. Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42 (2010), 30–35.
31. Noe, D.A., Rowinsky, E.K., Shen, H.S., Clarke, B.V., Grochow, L.B., McGuire, W.B., Hantel, A., Adams, D.B., Abeloff, M.D., Ettinger, D.S., et al. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). Cancer Res. 50 (1990), 4595–4599.
32. Novershtern, N., Subramanian, A., Lawton, L.N., Mak, R.H., Haining, W.N., McConkey, M.E., Habib, N., Yosef, N., Chang, C.Y., Shay, T., et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144 (2011), 296–309.
33. O'Donnell, E.F., Saili, K.S., Koch, D.C., Kopparapu, P.R., Farrer, D., Bisson, W.H., Mathew, L.K., Sengupta, S., Kerkvliet, N.I., Tanguay, R.L., Kolluri, S.K., The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS ONE, 5, 2010, e13128.
34. Okoye-Okafor, U.C., Bartholdy, B., Cartier, J., Gao, E.N., Pietrak, B., Rendina, A.R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K.J., et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat. Chem. Biol. 11 (2015), 878–886.
35. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
36. Sauvageau, G., Lansdorp, P.M., Eaves, C.J., Hogge, D.E., Dragowska, W.H., Reid, D.S., Largman, C., Lawrence, H.J., Humphries, R.K., Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc. Natl. Acad. Sci. USA 91 (1994), 12223–12227.
37. Schreiber, S.L., Kotz, J.D., Li, M., Aubé, J., Austin, C.P., Reed, J.C., Rosen, H., White, E.L., Sklar, L.A., Lindsley, C.W., et al., NIH Molecular Libraries Project Team. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell 161 (2015), 1252–1265.
38. Schwartsmann, G., Dodion, P., Vermorken, J.B., ten Bokkel Huinink, W.W., Joggi, J., Winograd, B., Gall, H., Simonetti, G., van der Vijgh, W.J., van Hennik, M.B., et al. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother. Pharmacol. 25 (1990), 345–351.
39. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
40. Sykes, D.B., Haynes, M.K., Waller, A., Garcia, M., Ursu, O., Gouveia, K.E., Sklar, L., Lewis, T.A., Dandapani, S., Munoz, B., et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. 2015, National Center for Biotechnology Information, Bethesda, MD.
41. Tedeschi, F.A., Zalazar, F.E., HOXA9 gene expression in the chronic myeloid leukemia progression. Leuk. Res. 30 (2006), 1453–1456.
42. Tora, L., Mullick, A., Metzger, D., Ponglikitmongkol, M., Park, I., Chambon, P., The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 8 (1989), 1981–1986.
43. Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340 (2013), 622–626.
44. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17 (2010), 225–234.
45. White, R.M., Cech, J., Ratanasirintrawoot, S., Lin, C.Y., Rahl, P.B., Burke, C.J., Langdon, E., Tomlinson, M.L., Mosher, J., Kaufman, C., et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471 (2011), 518–522.
46. Wisch, J.S., Griffin, J.D., Kufe, D.W., Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N. Engl. J. Med. 309 (1983), 1599–1602.
47. Wolf, C., Liu, S., Mei, X., August, A.T., Casimir, M.D., Regioselective copper-catalyzed amination of bromobenzoic acids using aliphatic and aromatic amines. J. Org. Chem. 71 (2006), 3270–3273.
48. Wu, Z., Irizarry, R.A., Gentleman, R., A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99 (2004), 909–917.
49. Yates, J.W., Wallace, H.J. Jr., Ellison, R.R., Holland, J.F., Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep. 57 (1973), 485–488.
50. Yuan, W., Payton, J.E., Holt, M.S., Link, D.C., Watson, M.A., DiPersio, J.F., Ley, T.J., Commonly dysregulated genes in murine APL cells. Blood 109 (2007), 961–970.
51. Zuber, J., Radtke, I., Pardee, T.S., Zhao, Z., Rappaport, A.R., Luo, W., McCurrach, M.E., Yang, M.-M., Dolan, M.E., Kogan, S.C., et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23 (2009), 877–889.